Author:
Funahashi H.,Tanaka Yuji,Imai T.,Wada M.,Tsukamura K.,Hayakawa Y.,Matsuura N.,Kikumori T.,Oiwa M.,Tominaga Y.,Takagi H.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference22 articles.
1. Slatopolsky E., Weerts C., Thielan J., Horst R., Harter H., Martin K.J. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J. Clin. Invest. 74: 2136, 1984.
2. Slatopolsky E., Berkoben M., Kelber J., Brown A., Delmez J. Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism. Kidney Int. 42: S43, 1992.
3. Finch J.L., Brown A.J., Mori T., Nishii Y., Slatopolsky E. Suppression of PTH and decreased action on bone are partially responsible for the low calcemic activity of 22-oxacalcitriol relative to 1,25-(OH)2D3. J. Bone Miner. Res. 7: 835, 1992.
4. Brown A.J., Ritter C.R., Finch J.L., Morrissey J., Martin K.J., Murayama E., Nishii Y., Slatopolsky E. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J. Clin. Invest. 84: 728, 1989.
5. Naveh-Many T., Silver J. Effects of calcitriol, 22-oxacalcitriol, and calcipotriol on serum calcium and parathyroid hormone gene expression. Endocrinology 133: 2724, 1993.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献